ompenaclid

DRUG3 trials

Sponsors

Inspirna Inc., Inspirna Inc., Inspirna, Inc.

Conditions

CRCColorectal CancerColorectal Cancer MetastaticColorectal CarcinomaColorectal NeoplasmsGastric CancerGastric NeoplasmGastrointestinal Cancer

Phase 1

A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

CompletedNCT03597581

Inspirna, Inc.Colorectal Cancer, Colorectal Cancer Metastatic, Colorectal Carcinoma +7

Start: 2018-06-05End: 2025-03-31Updated: 2025-04-03

Phase 2

A randomized Phase 2 Study of ompenaclid versus placebo in combination with FOLFIRI plus bevacizumab in patients with previously treated RAS mutant advanced or metastatic colorectal cancer

CompletedCTIS2023-503356-27-00

Inspirna Inc., Inspirna Inc.Metastatic colorectal cancer that is resistant to the currently approved methods of treatment is recognized as a serious threat to public health worldwide. Research efforts in recent years have become increasingly geared towards discovering and developing new treatment regimens with modes of action distinct from those of established agents and with the ability to target subclasses of colorectal cancer, such as those associated with RAS mutations.

Start: 2023-09-07End: 2025-04-02Target: 86Updated: 2024-07-03

A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

TerminatedNCT05983367

Inspirna, Inc.Colorectal Cancer, Metastatic Colon Cancer

Start: 2023-10-10End: 2025-03-31Updated: 2026-02-20

Related Papers

Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC).

Journal of Clinical Oncology2022-06-013 citations

Phase I monotherapy dose escalation of RGX-202, a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in patients with advanced gastrointestinal (GI) solid tumors.

Journal of Clinical Oncology2020-05-204 citations